MGMT and neoplasm: Significant differences among cohorts were evident for KPS, WHO tumor grade, histopathological subtype, IDH mutation status, 1p/19q codeletion, O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation, EOR, radiotherapy treatment, and chemotherapy treatment (all P < 0.001).